Most of the kinase inhibitors that are approved for therapeutic uses or that are undergoing clinical trials are directed toward the adenosine triphosphate (ATP) binding site of protein kinases. 5´-Fluorosulfonylbenzoyl 5´-adenosine (FSBA) is an activitybased probe (ABP) that covalently modifies a conserved lysine present in the nucleotide binding site of most kinases. Here the authors describe synthesis of FSBA derivatives, 2´-biotinyl-FSBA and 3´-biotinyl-FSBA as kinase ABPs, and delineate a Western blot method to screen and validate ATP competitive protein kinase inhibitors using biotinyl-FSBA as a nonselective activity-based probe for protein kinases. (Journal of Biomolecular Screening 2007:126-132) 
INTRODUCTION
P ROTEIN KINASES REPRESENT one of the largest protein superfamilies in eukaryotes. Based on functional classification of human genes, "about 530 genes, comprising"~2% of the total human genes, have been identified to encode protein kinases. 1 Because protein kinases function in a large number of distinct cell-signaling pathways, it is not surprising that several of the protein kinases have emerged as attractive targets for the identification and development of novel therapeutic agents for many disease indications. [2] [3] [4] Although progress has been made toward identification and evaluation of allosteric kinase inhibitors, the majority of the small-molecule kinase inhibitors studied so far bind to the Mg-adenosine triphosphate (ATP) complex binding pocket of protein kinases, and considerable progress has been made toward making these ATP competitive inhibitors potent and selective. [4] [5] [6] [7] [8] The recent clinical success of Gleevec (STI1571), Fasudil (Y-27632), Iressa (ZD1839), and Tarceva (OSI-774) underscores the promise of protein kinases as drug targets and demonstrates that inhibitors competitive with ATP can be useful for the treatment of human diseases. 7 Several groups have described the use of activity-based probes (ABPs) to monitor the functional state of enzyme families in complex mixtures. The enzyme families for which ABPs have been developed include serine hydrolases, [9] [10] [11] cysteine proteases, 12, 13 protein phosphatase, 14, 15 metalloproteases, 16 and lipid kinases. 17 Earlier we described the use of 5´-flurosulfonylbenzoyl 5´adenosine (FSBA) as a general ABP for the protein kinase family. 18 FSBA covalently labels most protein kinases by binding irreversibly to the ε-amino group of a conserved ATP pocket lysine. [18] [19] [20] [21] [22] Using autoradiography and liquid chromatography/ mass spectrometry (LC/MS) techniques, we showed that FSBA reacts with CDK2 and ALK5, 2 model proteins, only under native-like conditions. 18 Our studies concluded that FSBA labeling monitored by LC/MS can be used as a secondary screening method for the selection of selective ATP competitive protein kinase inhibitors.
Various biotin-tagged ABPs have been described to profile several classes of enzyme families, including serine hydrolase, [9] [10] [11] cysteine proteases, 12, 13 tyrosine phosphatase, 14, 15 and lipid kinases. 17 Biotinylated ABPs allow visualization of labeled proteins after Western blotting and, unlike the radioactive isotopes, can also be used as a handle for protein isolation by streptavidin-coated beads.
Although LC/MS provides a rapid and reproducible means to screen ATP competitor kinase inhibitors, its high cost and maintenance may limit laboratories from using it as a routine screening tool. In addition, in instances where proteins cannot yield good MS signals, use of LC/MS can be limited as a general screening tool. To address these shortcomings, we have developed chemically synthesized biotinylated FSBA probes for use in Western blot assays. Here we report the synthesis and characterization of 2´-biotinyl-FSBA and 3´-biotinyl-FSBA in which the biotin moiety is attached to the 2´ or 3´ hydroxyl moiety of the ribose group of FSBA, and we also describe their use as kinase ABPs to screen ATP competitor kinase inhibitors in a Western blot assay.
MATERIALS AND METHODS

Reagents
Purified protein kinases used in the present studies were the baculovirus-expressed kinase domain of the transforming growth factor (TGF)-β type I receptor, activin receptor-like kinase (ALK5) 23 (obtained from Ruth Lehr, GlaxoSmithKline [GSK]), full-length CDK2 24 (obtained from Dr. Warren Rocque, GSK), and Rho kinase I (ROCK I). 25 The molecular weights of purified ALK5, CDK2, and ROCK I, based on their primary amino acid sequences, are 34,974 Da, 33,972 Da, and 67,618 Da, respectively. The purity of all proteins was ~95%. FSBA, staurosporine, bovine serum albumin (BSA), and myoglobin were purchased from Sigma (St. Louis, MO). SB-431542, 18, 23 an ALK5-inhibitor, was purchased from Tocris Bioscience (Ellisville, MO). Stock solutions of FSBA (1 µM), biotinyl-FSBA (0.2 µM; see below for its synthesis), staurosporine (2 µM), and SB-431542 (10 µM) were prepared in 100% DMSO and stored at -80 °C. The final concentration of DMSO in all experiments was less than 5%. was added and, after allowing the mixture to warm to room temperature, was stirred overnight. The reaction was followed by analytical high-performance liquid chromatography (HPLC; Spherisorb S5 ODS2, 40%-60% B over 45 min: A = 0.1% trifluoroacetic acid [TFA]/water, B = 0.1% TFA/90% acetonitrile/10% water). The ratio of the isomers 5´-(p-Fluorosulfonylbenzoyl)-2´-(biotinyl)adenosine (2´-biotinyl-FSBA) and 5´-(p-Fluorosulfonylbenzoyl)-3´-(biotinyl)adenosine (3´-biotinyl-FSBA), produced during the reaction, changed with time, reaching equilibrium after overnight stirring.
Chemical synthesis of biotinyl-FSBA
The reaction mixture containing 2´-biotinyl-FSBA and 3´biotinyl-FSBA was evaporated to dryness, redissolved in the minimum volume of acetic acid/water/acetonitrile (10/40/50 by volume), and then purified by preparative HPLC (Hypersil 5µ BDS C8, 250 × 21.2 µm, 25%-50% B over 80 min). Fractions containing the 2´-biotinyl-FSBA (eluted first) and 3´-biotinyl-FSBA isomers ( Fig. 1) were pooled and then lyophilized. The recovery of 2´-biotinyl-FSBA (molecular mass, 680 Da) and 3´biotinyl-FSBA (molecular mass, 680 Da) was 10.2 mg and 9.8 mg, respectively. Solubility of these 2 forms of biotinyl-FSBA in DMSO was lower compared to FSBA. For validation studies, stock solutions (0.2 M in 50% DMSO) of both 2´-biotinyl-FSBA and 3´-biotinyl-FSBA were prepared and stored at -80 °C.
Liquid chromatography/mass spectrometry
LC/MS studies were carried out on an automated singlechannel LC/MS instrument, as described before. 18 The instrument components included Alliance HT™ Waters 2790 Separations Module (Waters, Milford, MA) with an autosampler, Waters 2487 dual-wavelength detector, LCT-ESI-TOF mass spectrometer (Micromass UK, Manchester, UK), and a system control computer (Model AP200, Compaq, 500 MHz). 26 The MS instrument was calibrated with NaI/CsI solution directly infused into the ESI interface at a flow rate of 25 µL/min. Reverse-phase HPLC parameters were essentially as described. 26 The flow rate was 0.3 to 0.5 µL/min for 1-or 2.1mm i.d. columns. UV absorbance was monitored at the 214-or 254-nm wavelength. LC/MS analysis of control and FSBA and biotinyl-FSBAmodified proteins was carried out as described before. 18 To follow modification, purified ALK5 kinase (5 µg) was incubated with 40 µM of either FSBA (Sigma) or 2´-biotinyl-FSBA or 3´biotinyl-FSBA at room temperature for various times (1-15 h), and a 10-µL aliquot of the mixture was injected onto the LC/MS, as described before. 18 Under these conditions, ALK5 was completely modified by FSBA within 30 min and by either form of biotinyl-FSBA in 3 h.
For ATP protection experiments, purified ALK5 (5 µg) was coincubated with 40 µM biotinyl-FSBA and various amounts of ATP (0.1-10 mM) for 3 h at room temperature, and the samples were subjected to LC/MS, as described above. All spectra were deconvoluted using the MaxEnt program, which is part of the MassLynx software (Micromass UK), as described. 18 Myoglobin was used as an external calibrant in all experiments.
SDS-PAGE and Western blotting
3´-Biotinyl-FSBA-labeled protein samples were prepared for Western blot as follows. Native or denatured purified protein samples were treated with 3´-biotinyl-FSBA for various times, as indicated in the figure legends, and then subjected to the Western blotting analysis. For selectivity/protection experiments, purified proteins were incubated with 3´-biotinyl-FSBA and ATP or SB-431542, as indicated in the figure legends, and then subjected to the Western blotting analysis. Control samples lacking biotinyl-FSBA and/or inhibitors were prepared under identical conditions. For the competition experiment, purified ALK5 kinase (5 µg) was first preincubated with various amounts of SB-431542 (1-10 µM) for 15 min at room temperature. After adding 3´-biotinyl-FSBA (10 µM), the reaction mixture was incubated at room temperature for an additional 2 h. For the control samples, no SB-431542 or 3´-biotinyl-FSBA was added. All samples were subjected to SDS-PAGE and Western blot as described below.
For Western blots, aliquots of control and the biotinyl-FSBAtreated sample were subjected to 12% SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes by electroblotting. After transfer, the membranes were blocked in Tris-buffered saline (TBS) with 1% Tween (TBS-Tween) and 3% (wt/vol) nonfat dry milk for 1 h at room temperature. Blots were then treated with an avidin-horseradish peroxidase conjugate (Bio-Rad, 1:1000 dilution) in TBS-Tween with 3% nonfat dry milk for 1 h at room temperature. The blot was washed with TBS-Tween 3 times (5-10 min each wash) and then treated with Supersignal West Pico Chemiluminescent substrate (Pierce, Rockford, IL) for 1 min. The blot was exposed and developed by using an AlphaImager 2000 (Alpha Innotech, San Leandro, CA). After development, the same blot was stained with Coomassie blue stain to visualize protein bands.
RESULTS
Synthesis of biotinylated FSBA (biotinyl-FSBA)
We recently described the use of FSBA, 7-9 an ATP analog, as an activity-based probe for protein kinases. 18 FSBA covalently modifies a conserved lysine present in the nucleotide binding sites of most protein kinases. [18] [19] [20] [21] To generate biotin-tagged FSBA, we built on the earlier work of Scoggins et al. 20 by modifying the free hydroxyl groups of the ribose ring of FSBA with biotin ( Fig. 1) . To effect a similar attachment to the hydroxyl groups, the symmetrical anhydride of (+)-biotin was prepared using diisopropylcarbodiimide in DMF. This reacted readily with FSBA in the presence of dimethylaminopyridine but gave mainly a mixture of the 2´,3´ bis-substituted product and unreacted starting material, even when using only a 1.5 molar excess of anhydride. A more efficient method was developed using an HOBt/HBTU-mediated coupling, as described in Materials and Methods. The reaction was followed by analytical HPLC, which indicated that the ratio of substitution on the ribose ring changed with time, with the 2´-isomer forming in greater proportions at the start but equilibrating to an approximately equal 2´-/3´mixture after overnight reaction. Purification was achieved by reverse-phase HPLC and fractions analyzed by electrospray LC/MS and analytical HPLC. Under the acidic solvent conditions, there was no indication of biotin transfer between the 2´-and 3´-hydroxy groups and, after lyophilization, they were stored at -80 °C until use.
Biotinyl-FSBA labeling of ALK5 analyzed by LC/MS
Earlier we showed that the covalent modification of protein kinases by FSBA can be followed by the LC/MS technique. 18 For example, incubation in the presence of FSBA caused a shift in the molecular mass of ALK5 by 433 Da, which accounted for the presence of the covalently attached sulfonylbenzoyl adenosine moiety with the removal of the fluorine atom. To evaluate if biotinyl-FSBA has similar properties, we first subjected control and 2´-or 3´-biotinyl-FSBA-treated ALK5 to LC/MS, as described in Materials and Methods. As shown in Figure 2A , treatment with 3´-biotinyl-FSBA (40 µM) treated ALK5 (5 µg) showed an increase in the molecular mass of ALK5 by 660 Da. Similar results were obtained with 2´biotinyl-FSBA (not shown). Because both 2´-and 3´-biotin moieties have a 680-Da mass, the difference in the unmodified and 2´-or 3´-biotinyl-FSBA modified form of ALK5 accounts for the presence of the covalently attached sulfonylbenzoyl adenosine moiety in the ATP binding pocket with the removal of the fluorine atom. Importantly, longer incubation times (up to 20 h) with either FSBA or 2´-biotinyl-FSBA or 3´-biotinyl-FSBA showed no additional modification (Fig. 2B) , indicating that FSBA and its biotin derivatives react with the conserved lysine in the ATP binding pocket of ALK5. 18 Our earlier autoradiography and LC/MS studies showed that ATP competes with FSBA modification of ALK5 kinase in a concentration-dependent fashion. To examine if biotin-tagged FSBA has similar characteristics, ALK5 kinase (5 µg) was coincubated in the presence of 3´-biotinyl-FSBA and varying amounts of ATP (0-0.5 µM), as described in Materials and Methods. As shown in Figure 2C , ATP blocked covalent modification of ALK5 by 3´-biotinyl FSBA in a concentration-dependent fashion.
Biotinyl-FSBA labeling of ALK5 analyzed by Western blot
The LC/MS experiments described above indicated that biotinyl-FSBA has properties similar to those of FSBA as kinase ABP. As an alternative to the LC/MS technique, we evaluated biotinyl-FSBA's utility as an ABP for protein kinases in a Western blot format. 9, 15 First, to test reactivity of biotinyl-FSBA, we incubated purified ALK5 (0.01-5 µg) with 3´-biotinyl-FSBA (40 µM) for 2 h at room temperature. The samples were either heated at 95 °C or kept on ice for 10 min prior to the addition of biotinyl-FSBA. Samples were then subjected to SDS-PAGE (12%) for Western blotting analysis, as described in Materials and Methods. As depicted in Figure 3A , 3´-biotinyl-FSBA specifically labeled unheated (lane 2) but not heat-denatured (lane 1) preparations of ALK5. Similar results were obtained with ROCK I kinase (not shown). As shown in Figure 3B , 3´-biotinyl-FSBA reacted with ALK5 kinase in a concentration-dependent manner (lanes 1-6). At least 100 ng of purified ALK5 (Fig. 3B, lane 2) gave a detectable and reproducible signal under the conditions employed in this experiment. In addition, the Western blotting (Fig. 3C, top  panel) and Coomassie blue staining of the gel (Fig. 3C , bottom panel) indicate that coincubation with ATP blocked binding of 3´biotinyl-FSBA to ALK5 in a dose-dependent manner. These results further confirm that that biotinyl-FSBA and ATP are competing for the same binding pocket in ALK5 kinase. Together, these results confirm that, similar to FSBA, 18 biotinyl-FSBA reacts only with the native-like conformation of protein kinase and further validate the use of biotinyl-FSBA as kinase ABP in a Western blot format.
Effects of ATP competitor kinase inhibitors
The ATP protection experiments suggested that ATP competitor small-molecule protein kinase inhibitors, which also encompass the ATP binding pocket, would also prevent covalent modification of protein kinases by biotinyl-FSBA. Earlier we showed that SB-431542, a potent and selective ALK5 kinase inhibitor, 23 abrogated FSBA labeling of ALK5 but not CDK2 kinase. 18 To evaluate if SB-431542 would also compete with the binding of biotinyl-FSBA to ALK5 but not CDK2, purified ALK5 and CDK2 proteins were coincubated with 3´-biotinyl-FSBA (40 µM) and SB-431542 (20 µM). As shown in Figure  4A , as predicted, SB-431432 completely blocked the binding of 3´-biotinyl-FSBA to ALK5 but not CDK2. Furthermore, as shown in Figure 4B , SB-431542 abrogated biotin-FSBA labeling of ALK5 in a concentration-dependent manner. Together, these results further validate the use of biotinyl-FSBA as a kinase ABP and indicate that biotinyl-FSBA modification of protein kinases monitored by Western blotting can be used to screen and identify selective ATP competitive kinase inhibitors.
DISCUSSION
Earlier we evaluated and validated FSBA as an ABP for protein kinases. 18 In the present study, we have described the synthesis of FSBA derivatives, 2´-biotinyl-FSBA and 3´-biotinyl-FSBA, and delineated a Western blot method to screen and validate ATP competitive protein kinase inhibitors using biotinyl-FSBA as a general ABP for protein kinases.
Based on the studies of Scoggins et al., 20 we synthesized 2´biotinyl-FSBA and 3´-biotinyl-FSBA where biotin was attached via its carboxylic acid to the 2´-or 3´-hydroxyl moiety of the ribose group of FSBA. The ATP and staurosporine protection studies confirmed that the mode of labeling of biotinyl-FSBA to protein kinases was identical to that of FSBA. 18, 21 LC/MS results also showed that compared to FSBA, the reactivity of both forms of biotinyl-FSBA to purified kinases was slower (not shown). The bulky biotin group of biotinyl-FSBA may be the cause of lower solubility and reactivity compared to FSBA. It is possible that by varying the size and nature of the linker, the reactivity and solubility of biotinyl-FSBA could be improved. [9] [10] [11] In general, we have found LC/MS techniques to be quite useful to directly compare the reactivity of the various forms of FSBA (unpublished data).
In the past few years, several groups have described innovative chemical approaches to dissect functions of various enzyme families. [27] [28] [29] [30] The biotin-tagged and fluorescent-tagged (such as rhodamine and BODIPY) ABPs have been used for proteomic as well as inhibitor profiling studies. Our LC/MS 18 and Western blot (Fig. 4B ) studies have shown that FSBA and its biotin-tagged versions can be used to screen and validate ATP competitive kinase inhibitors using LC/MS or Western blot techniques. We are currently assessing if the biotin-and fluorescent-tagged FSBA probes would also have utility in profiling activities of protein kinases in cellular extracts and complex proteome.
